Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 22, Issue 16, 2004, Pages 3238-3247

  Pérez Soler, Román ^a   Chachoua, Abraham ^a   Hammond, Lisa A ^a   Rowinsky, Eric K ^a   Huberman, Mark ^a   Karp, Daniel ^a   Rigas, James ^a   Clark, Gary M ^a   Santabárbara, Pedro ^a   Bonomi, Philip ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PLATINUM; QUINAZOLINE DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DIARRHEA; DISEASE SEVERITY; DRUG ERUPTION; DRUG TOLERABILITY; HEALTH CARE ORGANIZATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; QUESTIONNAIRE; STAINING; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; ADULT; AGED; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; FEMALE; LUNG TUMOR; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; RASH; SURVIVAL;

ADMINISTRATION, ORAL; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DIARRHEA; EXANTHEMA; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 4344646459     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.11.057     Document Type: Article

References (44)

1. Modijtahedi H, Dean C: The receptor for EGF and its ligands: Expression, prognostic value and target for therapy in cancer. Int J Oncol 4:277-296, 1994
2. Gullick WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 47:87-98, 1991
3. Salomon DS, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995
4. Rusch V, Mendelsohn J, Dmitrovsky E: The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev 7:133-141, 1996
5. Davies DE, Chamberlin SG: Targeting the epidermal growth factor receptor for therapy of carcinomas. Biochem Pharmacol 51:1101-1110, 1996
6. Baselga J, Mendelsohn J: The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 29:127-138, 1994
7. Lei W, Mayotte JE, Levitt ML: Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells. Anticancer Res 19:221-228, 1999
8. Veale D, Kerr N, Gibson GJ, et al: The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 68:162-165, 1993
9. Rusch V: Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3:515-522, 1997
10. Ohsaki Y: EGFR expression correlates poor prognosis in non-small cell lung cancer (NSCLC) patients interacting with p53 overexpression. Proc Am Assoc Cancer Res 38:1997 (abstr 2191a)
11. Veale D, Kerr N, Gibson GJ, et al: Characterization of epidermal growth factor receptor in primary human non-small cell lung cancer. Cancer Res 49:1313-1317, 1989
12. Sekine I, Takami S, Guang SG, et al: Role of epidermal growth factor receptor overexpression, K-ras point mutation and c-myc amplification in the carcinogenesis of non-small cell lung cancer. Oncol Rep 5:351-354, 1998
13. Rusch V, Klimstra D, Linkov I, et al: Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res 55:1365-1372, 1995
14. Pfeiffer P, Clausen PP, Andersen K, et al: Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: An immunohistochemical study on cryosections. Br J Cancer 74:86-91, 1996
15. Cerny T, Barnes DM, Hasleton P, et al: Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer 54:265-269, 1986
16. IMPATH Inc: Analysis of EGFr expression in a selection of tumor types. New York, NY, IMPATH Inc, IMPATH Study no. PFZ04; PFZ04: 1-16, 1998-1999
17. Reissmann PT, Koga H, Figlin RA, et al: Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group. J Cancer Res Clin Oncol 125:61-70, 1999
18. Pollack VA, Savage DM, Baker DA, et al: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291:739-748, 1999
19. Ng SS, Tsao MS, Nicklee T, et al: Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 1:777-783, 2002
20. Hidalgo M, Siu LL, Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279, 2001
21. Bergman B, Aaronson NK, Ahmedzai S, et al: The EORTC QLQ-LC13: A modular supplement to the EORTC core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 30A:635-642, 1994
22. World Health Organization: Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, 1979, publication 48
23. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
24. Gehan EA, Lemak NA: Statistics in Medical Research. Developments in Clinical Trials. New York, NY, Plenum Medical Book Company, 1994
25. Gandara DR, Vokes E, Green M, et al: Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial. J Clin Oncol 18:131-135, 2000
26. Fossella FV, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354-2362, 2000
27. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000
28. Perez-Soler R, Mendelsohn J: Growth factor receptors as a target of therapy, in: Lung Cancer. Malden, MA, Blackwell Science Inc. 1998, pp 309-341
29. Lin C, Tsao MS: In vitro and in vivo expressions of transforming growth factor-alpha and tyrosine kinase receptors in human non-small-cell lung carcinomas. Am J Pathol 14:1155-1162, 1993
30. Garcia de Palazzo IE, Adams GP, Sundareshan P, et al: Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 53:3217-3220, 1993
31. Clark GM, Pérez-Soler R, Siu L, et al: Rash severity is predictive of increased survival with erlotinib HCl. Proc Am Soc Clin Oncol 22:196, 2003 (abstr 786)
32. Saltz L, Kies M, Abbruzzese JL, et al: The presence and intensity of the cetuximab-induced acne like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 22:204, 2003 (abstr 817)
33. Cohen EE, Rosen F, Stadler WM, et al: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980-1987, 2003
34. Rowinsky E, Schwartz G, Dutcher J, et al: ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFr) monoclonal antibody: Phase II clinical trials in renal cell cancer (RCC). Eur J Cancer 38:57, 2002 (abstr 178)
35. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246, 2003
36. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003
37. Herndon JE II, Fleishman S, Kornblith AB, et al: Is quality of life predictive of the survival of patients with advanced non-small cell lung carcinoma? Cancer 85:333-340, 1999
38. Ramnath N, Hernandez FJ, Tan DF, et al: MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. J Clin Oncol 19:4259-4266, 2001
39. Naruse I, Ohmori T, Ao Y, et al: Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer 98:310-315, 2002
40. Dai Q, Ling Y-H, Iwata KK, et al: Enhanced sensitivity to the HER1/EGFR tyrosine kinase inhibitor erlotinib HCl (Tarceva. OSI-774) in chemotherapy-resistant tumor cell lines. Proc Am Assoc Cancer Res 44: 968, 2003 (abstr 4865)
41. Baselga J, Rischin D, Ranson M, et al: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292-4302, 2002
42. Perez-Soler R, Kemp B, Wu QP, et al: Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 6:4932-4938, 2000
43. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
44. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004